Anika Therapeutics Stock Guidance | NASDAQ:ANIK

Comments

Anika Therapeutics Inc Stock Guidance

ANIKNASDAQ

Trade with Public

$13.88

-0.37-2.56%

Last update: Mar 6, 1:28 PM

Overview News Earnings OptionsGuidanceAnalyst Ratings Insider Trades Short Interest Stock Report

Anika Therapeutics (ANIK) last issued guidance on February 26, 2026 for fiscal year 2026. The company guided revenue in the range of $114.00M - $122.50M for the period.

Compared to prior guidance, Anika Therapeutics lowered its revenue forecast from a prior range of $168.00M - $173.00M.

Anika Therapeutics has issued 8 guidance updates between March 6, 2023 and February 26, 2026. During this period, the company raised its outlook 2 times and lowered it 1 time, providing investors with insight into management's evolving expectations.

Latest Guidance Date

Feb 26, 2026

Guidance Period

Full Year 2026

Revenue Guidance Range

$114.00M - $122.50M

Anika Therapeutics Guidance History

Review all historical guidance issued by Anika Therapeutics, including EPS and revenue forecasts across quarterly and annual periods.

FAQ

What is the most recent guidance for Anika Therapeutics (ANIK)?

The most recent guidance for Anika Therapeutics (ANIK) was reported on February 26, 2026 for the fiscal year 2026. Anika Therapeutics forecasted revenue between $114.00M and $122.50M for the period.

What revenue range did Anika Therapeutics (ANIK) guide for?

Anika Therapeutics (ANIK) guided revenue in the range of $114.00M to $122.50M for the fiscal year 2026.

Did Anika Therapeutics (ANIK) raise or lower guidance?

Anika Therapeutics (ANIK) lowered its revenue guidance from a prior range of $168.00M - $173.00M to $114.00M - $122.50M for the fiscal year 2026.

When did Anika Therapeutics (ANIK) last issue guidance?

Anika Therapeutics (ANIK) last issued guidance on February 26, 2026 for the fiscal year 2026.

People Also Watch

Molecular Partners AG

NASDAQ:MOLN

$5.15

1.52%

Kalaris Therapeutics Inc

Galectin Therapeutics Inc

NASDAQ:GALT

$3.01

1.32%

Voyager Therapeutics Inc

NASDAQ:VYGR

$3.84

-2.42%

Burning Rock Biotech Ltd

NASDAQ:BNR

$24.60

-1.14%

Elicio Therapeutics Inc

NASDAQ:ELTX

$11.37

-3.85%

Eledon Pharmaceuticals Inc

NASDAQ:ELDN

$2.65

1.91%

Anika Therapeutics (ANIK) last issued guidance on February 26, 2026 for fiscal year 2026. The company guided revenue in the range of $114.00M - $122.50M for the period.

Compared to prior guidance, Anika Therapeutics lowered its revenue forecast from a prior range of $168.00M - $173.00M.

Latest Guidance Date

Feb 26, 2026

Guidance Period

Full Year 2026

Revenue Guidance Range

$114.00M - $122.50M

Anika Therapeutics Guidance History

Review all historical guidance issued by Anika Therapeutics, including EPS and revenue forecasts across quarterly and annual periods.

											Get Alert
02/26/2026	ANIK	Anika Therapeutics	FY	2026	—	—	—	$114.00M	$122.50M	$114.22M	Get Alert
08/08/2024	ANIK	Anika Therapeutics	FY	2024	—	—	—	$168.00M	$173.00M	$170.84M	Get Alert
05/08/2024	ANIK	Anika Therapeutics	FY	2024	—	—	—	$168.00M	$173.00M	$170.27M	Get Alert
03/13/2024	ANIK	Anika Therapeutics	FY	2024	—	—	—	$168.00M	$173.00M	$179.42M	Get Alert
11/02/2023	ANIK	Anika Therapeutics	FY	2023	—	—	—	$164.00M	$166.00M	$161.29M	Get Alert
08/08/2023	ANIK	Anika Therapeutics	FY	2023	—	—	—	$159.50M	$163.00M	$161.84M	Get Alert
05/09/2023	ANIK	Anika Therapeutics	FY	2023	—	—	—	$158.00M	$163.00M	$161.06M	Get Alert
03/06/2023	ANIK	Anika Therapeutics	FY	2023	—	—	—	$158.00M	$163.00M	$168.40M	Get Alert

FAQ

What is the most recent guidance for Anika Therapeutics (ANIK)?

The most recent guidance for Anika Therapeutics (ANIK) was reported on February 26, 2026 for the fiscal year 2026. Anika Therapeutics forecasted revenue between $114.00M and $122.50M for the period.

What revenue range did Anika Therapeutics (ANIK) guide for?

Anika Therapeutics (ANIK) guided revenue in the range of $114.00M to $122.50M for the fiscal year 2026.

Did Anika Therapeutics (ANIK) raise or lower guidance?

Anika Therapeutics (ANIK) lowered its revenue guidance from a prior range of $168.00M - $173.00M to $114.00M - $122.50M for the fiscal year 2026.

When did Anika Therapeutics (ANIK) last issue guidance?

Anika Therapeutics (ANIK) last issued guidance on February 26, 2026 for the fiscal year 2026.

People Also Watch

Molecular Partners AG

NASDAQ:MOLN

$5.15

1.52%

Kalaris Therapeutics Inc

Galectin Therapeutics Inc

NASDAQ:GALT

$3.01

1.32%

Voyager Therapeutics Inc

NASDAQ:VYGR

$3.84

-2.42%

Burning Rock Biotech Ltd

NASDAQ:BNR

$24.60

-1.14%

Elicio Therapeutics Inc

NASDAQ:ELTX

$11.37

-3.85%

Eledon Pharmaceuticals Inc

NASDAQ:ELDN

$2.65

1.91%

											Get Alert
02/26/2026	ANIK	Anika Therapeutics	FY	2026	—	—	—	$114.00M	$122.50M	$114.22M	Get Alert
08/08/2024	ANIK	Anika Therapeutics	FY	2024	—	—	—	$168.00M	$173.00M	$170.84M	Get Alert
05/08/2024	ANIK	Anika Therapeutics	FY	2024	—	—	—	$168.00M	$173.00M	$170.27M	Get Alert
03/13/2024	ANIK	Anika Therapeutics	FY	2024	—	—	—	$168.00M	$173.00M	$179.42M	Get Alert
11/02/2023	ANIK	Anika Therapeutics	FY	2023	—	—	—	$164.00M	$166.00M	$161.29M	Get Alert
08/08/2023	ANIK	Anika Therapeutics	FY	2023	—	—	—	$159.50M	$163.00M	$161.84M	Get Alert
05/09/2023	ANIK	Anika Therapeutics	FY	2023	—	—	—	$158.00M	$163.00M	$161.06M	Get Alert
03/06/2023	ANIK	Anika Therapeutics	FY	2023	—	—	—	$158.00M	$163.00M	$168.40M	Get Alert

Benzinga

Benzinga

Anika Therapeutics Inc Stock Guidance

Anika Therapeutics Guidance History

FAQ

What is the most recent guidance for Anika Therapeutics (ANIK)?

What revenue range did Anika Therapeutics (ANIK) guide for?

Did Anika Therapeutics (ANIK) raise or lower guidance?

When did Anika Therapeutics (ANIK) last issue guidance?

People Also Watch

Anika Therapeutics Guidance History

FAQ

What is the most recent guidance for Anika Therapeutics (ANIK)?

What revenue range did Anika Therapeutics (ANIK) guide for?

Did Anika Therapeutics (ANIK) raise or lower guidance?

When did Anika Therapeutics (ANIK) last issue guidance?

People Also Watch